А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding pilot study
to assess the efficacy and safety of CD-008-0045 in patients with Generalized Anxiety
Disorder (GAD). Each patient will participate in the study for the period of approximately 10
weeks: Screening and Run-in period: 1 week; Study Treatment period: 8 weeks; Follow-up
period: 1 week.